MedTrace Logo

Ertapenem Versus Meropenem/Imipenem for ESBL+ Gram-negative Infections

NCT01297842 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2012-01-02

No results posted yet for this study

Summary

Adult patients with ESBL-producing Gram negative infections are randomized to receive ertapenem or meropenem/imipenem. Clinical and microbiological responses between both groups are compared.

Conditions

  • Drug Safety

Interventions

DRUG

Ertapenem

Ertapenem 1 gram per day for 7 to 14 days

DRUG

Meropenem or Imipenem

Meropenem or Imipenem 0.5 to 1 gram 3 to 4 times per day for 7 to 14 days

Sponsors & Collaborators

  • Mahidol University

    lead OTHER

Principal Investigators

  • Visanu Thamlikitkul, MD · Siriraj Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2013-04-30
Completion
2013-08-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01297842 on ClinicalTrials.gov